Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivonescimab + FOLFOX
- Development stage
- Unknown
- Lead developer
- Summit Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Intra-arterial
01
Overview
Ivonescimab (AK112) is a first-in-class bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). This dual-action biologic is designed to enhance anti-tumor immune responses while inhibiting tumor angiogenesis. In the context of the Tianjin Medical University study, it is combined with Hepatic Arterial Infusion Chemotherapy (HAIC) using the FOLFOX regimen (oxaliplatin, 5-fluorouracil, and leucovorin). This combination therapy is being evaluated for the treatment of unresectable BCLC stage B or C hepatocellular carcinoma (HCC), aiming to provide superior efficacy by delivering high concentrations of chemotherapy directly to the liver alongside systemic immunotherapy and anti-angiogenic support.
- Other names
- Ivonescimab + HAICAK112 + HAICAK112 + FOLFOX
02
Targets
VEGF (VEGF family)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on ivonescimab + FOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivonescimab + FOLFOX.